Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis

Archives of Pharmacal Research

Volumn 34, Issue 3, 2011, Pages 399-405

  Lee, Jue Hee ^a   Jang, Eui Chan ^b   Han, Yongmoon ^a  

^a Dongduk Women's University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Augmentation; Candida albicans; Combination immunotherapy; Disseminated candidiasis; Fluconazole; MAb B6.1

Indexed keywords

FLUCONAZOLE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B6.1; MONOCLONAL ANTIBODY S9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANDIDA ALBICANS; COLONY FORMING UNIT; COMBINATION IMMUNOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOTHERAPY; INVASIVE CANDIDIASIS; KIDNEY; MEAN SURVIVAL TIME; MOUSE; NONHUMAN; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; IMMUNOGLOBULIN M; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; TRISACCHARIDES;

EID: 79959944869     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0307-9     Document Type: Article

References (33)

1. Antachopoulos, C., Walsh, T. J., and Roilides, E., Fungal infections in primary immunodeficiencies. Eur. J. Pediatr., 166, 1099-1117 (2007). (Pubitemid 47476633)
2. Bodey, G. P., The emergence of fungi as major hospital pathogens. J. Hosp. Infect., 11 Suppl A, 411-426 (1988).
3. Brawner, D. L. and Cutler, J. E., Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candid albicans. Infect. Immun., 51, 327-336 (1986). (Pubitemid 16200038)
4. Caesar-TonThat, T. C. and Cutler, J. E., A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun., 65, 5354-5357 (1997). (Pubitemid 27513594)
5. Dixon, T. C., Steinbach, W. J., Benjamin, D. K. Jr., Williams, L. W., and Myers, L. A., Disseminated Candida tropicalis in a patient with chronic mucocutaneous candidiasis. South Med. J., 97, 788-790 (2004). (Pubitemid 39108735)
6. Edwards, J. E., Invasive Candida infections: evolution of a fungal pathogen. N. Engl. J. Med., 324, 1060-1072 (1991).
7. Edwards, J. E., Bodey, G. P., Boeden, R. A., Buchner, T., DePauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., Kohno, S., Martino, P., Meunier, F., Mori, T., Pfaller, M. A., Rex, J. H., Rogers, T. R., Rubin, R. H., Solomkin, J., Viscoli, C., Walsh, T. J., and White, M., International conference for the development of a consensus on the management and prevention of severe candidalinfections. Clin. Infect. Dis., 25, 43-59 (1997).
8. Epstein, J. B. and Polsky, B., Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin. Ther., 20, 40-57 (1998). (Pubitemid 28126279)
9. Filler, S. G. and Edwards, J. E., When and how to treat serious candidial infections: concepts and controversies. Curr. Clin. Top. Infect. Dis., 15, 1-18 (1995).
10. Fisher-Hoch, S. P. and Hutwagner, L., Opportunisticcandidiasis: an epidemic of the 1980s. Clin. Infect. Dis., 21, 897-904 (1995).
11. Fonos, V. and Cataldi, L., Amphotericin B-induced nephrotoxicity: a Review. J. Chemother., 12, 463-470 (2000). (Pubitemid 32048160)
12. Graybill, J. R., Editorial response: can we agree on the treatment of candidiasis? Clin. Infect. Dis., 25, 60-62 (1997).
13. Gupta, A. K., Sauder, D. N., and Shear, N. H., Antifungal agents: an overview. Part II. Am. Acad. Dermatol., 30, 911-933 (1994).
14. Gupta, A. K., Katz, H. I., and Shear, N. H., Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J. Am. Acad. Dermatol., 41, 237-249 (1999). (Pubitemid 29379711)
15. Han, Y. and Cutler, J. E., Antibody response that protects against disseminated candidasis. Infect. Immun., 63, 2714-2719 (1995).
16. Han, Y. and Cutler, J. E., Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis., 15, 1169-1175 (1997). (Pubitemid 27176506)
17. Han, Y., Kanbe, T., Cherniak, R., and Cutler, J. E., Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun., 65, 4100-4107 (1997). (Pubitemid 27422065)
18. Han, Y., Morrison, R. P., and Cutler, J. E., A vaccine and monoclonal antibodies that Enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun., 66, 5771-5776 (1998). (Pubitemid 28531833)
19. Han, Y., Riesselman, M., and Cutler, J. E., Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun., 68, 1649-1654 (2000). (Pubitemid 30108568)
20. Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S., Carroll, M. C., and Cutler, J. E., Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol., 67, 1550-1557 (2001). (Pubitemid 32703155)
21. Han, Y. and Lee, J. H., Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol. Pharm. Bull., 28, 541-544 (2005). (Pubitemid 40879986)
22. Han, Y., Synergic anticandidal effect of epigallocatechin-Ogallate combined with amphotericin B in a murine model of disseminated candidiasis and its anticandidal mechanism. Biol. Pharm. Bull., 30, 1693-1696 (2007). (Pubitemid 47403247)
23. Han, Y., Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis. Int. Immunopharmacol., 10, 1526-1531 (2010).
24. Jin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X., and Yu, L., The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Lett. Appl. Microbiol., 51, 351-357 (2010).
25. Kofla, G., Turner, V., Schulz, B., Storch, U., Froelich, D., Rognon, B., Coste, A. T., Sanglard, D., and Ruhnke, M., Doxorubicin induces drug efflux pumps in Candida albicans. Med. Mycol., 49, 132-142 (2011).
26. MacNeill, C., Weisz, J., and Carey, J. C., Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. J. Reprod. Med., 48, 63-68 (2003). (Pubitemid 36249747)
27. Masia Canuto, M. and Gutierrez Rodero, F., Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis., 2, 550-563 (2002).
28. Mayer, J., Doubek, M., Doubek, J., Horky, D., Scheer, P., and Stepanek, M., Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis., 186, 379-388 (2002). (Pubitemid 34816321)
29. Pincus, S. H., Cole, R. L., Kamanga-Sollo, E., and Fischer, S. H., Interaction of group B steptococcal opacity variants with the host defense system. Infect. Immun., 61, 3761-3768 (1993). (Pubitemid 23260048)
30. Rex, J. H., Walsh, T. J., and Anaissie, E. J., Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med., 43, 321-371 (1998).
31. Sanglard, D., Clinical relevance of mechanism of antifungal drug resistance in yeasts. Enferm. Infecc. Microbiol. Clin., 20, 462-469 (2002).
32. Schaberg, D. R., Culver, D. H., and Gayner, R. P., Major trends in the microbial etiological nosocomial infection. Am. J. Med., 16, 72-75 (1991).
33. Sieck, T. G., Moors, M. A., Buckley, H. R., and Blank, K. J., Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect. Immun., 61, 3540-3543 (1993). (Pubitemid 23223452)